COST-EFFECTIVENESS ANALYSIS (CEA) BETWEEN ERLOTINIB AND GEFITINIB FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN THAILAND

被引：0
|
作者：
Prasongsook, Naiyarat [1 ]
Jaruhathai, Sureerat [1 ]
Maoleekulpairoj, Savitree [1 ]
Sooksriwong, Chaoncin [1 ]
机构：
[1] Mahidol Univ, Fac Pharm, Bangkok 10700, Thailand
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
TK1; Cost-effectiveness; gefitinib; erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1245 / S1246
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA
    Ciuleanu, T. E.
    Dediu, M.
    Minea, L. N.
    Baculea, S.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A38 - A38
  • [2] A COMPARATIVE CLINICAL AND COST-EFFECTIVENESS EVALUATION OF GEFITINIB AND ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Lopes, Gilberto D. L., Jr.
    Segel, Joel
    Tan, Daniel
    Do, Young
    Mok, Tony
    Finkelstein, Eric
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1306 - S1307
  • [3] Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel
    Oscar Arrieta
    Pablo Anaya
    Vicente Morales-Oyarvide
    Laura Alejandra Ramírez-Tirado
    Ana C. Polanco
    [J]. The European Journal of Health Economics, 2016, 17 : 855 - 863
  • [4] Effectiveness and cost of gefitinib in advanced/metastatic non-small cell lung cancer
    Selvi-Sabater, P.
    Sanchez-Martinez, I.
    Sadyrbaeva-Dolgova, S.
    Portillo-Haro, S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 289 - 289
  • [5] Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel
    Arrieta, Oscar
    Anaya, Pablo
    Morales-Oyarvide, Vicente
    Alejandra Ramirez-Tirado, Laura
    Polanco, Ana C.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2016, 17 (07): : 855 - 863
  • [6] Gefitinib or Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer
    Shao, Yu-Yun
    Lin, Chia-Chi
    Yang, Chih-Hsin
    [J]. DISCOVERY MEDICINE, 2010, 9 (49) : 538 - 545
  • [7] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S165 - S166
  • [8] Comparison of gefitinib and erlotinib for Korean patients with advanced non-small cell lung cancer
    Lee, Jin Hwa
    Jo, You Ri
    Park, Hye Sung
    Ryu, Yon Ju
    Chun, Eun Mi
    Chang, Jung Hyun
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S692 - S692
  • [9] Cost effectiveness of erlotinib in the treatment of advanced non small cell lung cancer (NSCLC) in Poland
    Orlewska, E.
    Szczesna, A.
    Gyldmark, M.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A279 - A279
  • [10] Cost-effectiveness analysis (CEA) of third-line erlotinib therapy compared to best supportive care for advanced non-small cell lung cancer (NSCLC) in British Columbia (BC)
    van der Hoek, K.
    Taylor, S. C.
    Peacock, S.
    Johnston, K.
    Melosky, B. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345